See my other comment. 20 years may be too long for some industries (software), but may not be long enough/ structured properly for R&D heavy industries like pharmaceuticals and biosciences.

Biologics (all the -mab drugs, monoclonal antibodies, adalimumab Humira) are a treat because you have to share your methodology, but you do not have to share your cell culture line. Since the cell line itself needs to be approved, the me-too's have to go through ALL the trouble themselves.